【摘 要】
：
Solid tumors are complex entities,comprising a wide variety of malignancies with very different molecular alterations.Despite this,they share a set of characteristics known as“hallmarks of cancer”that can be used as common therapeutic targets.Thus,every t
【机 构】
：
Departamento de Ingeniería Química y Tecnología Farmacéutica,Universidad de La Laguna,La Laguna 3820
论文部分内容阅读
Solid tumors are complex entities,comprising a wide variety of malignancies with very different molecular alterations.Despite this,they share a set of characteristics known as“hallmarks of cancer”that can be used as common therapeutic targets.Thus,every tumor needs to change its meta-bolism in order to obtain the energy levels required for its high proliferative rates,and these adaptations lead to alterations in extra-and intracellular pH.These changes in pH are common to all solid tumors,and can be used either as therapeutic targets,blocking the cell proton transporters and reversing the pH changes,or as means to specifically deliver anticancer drugs.In this review we will describe how proton transport inhibitors in association with nanocarriers have been designed to block the pH changes that are needed for cancer cells to survive after their metabolic adaptations.We will also describe studies aiming to decrease intracellular pH in cancer using nanoparticles as molecular cages for protons which will be released upon UV or IR light exposure.Finally,we will comment on several studies that have used the extracellular pH in cancer for an enhanced cell internalization and tumor penetration of nanocarriers and a controlled drug delivery,describing how nanocarriers are being used to increase drug stability and specificity.
其他文献
Many sensitizers have not only photodynamic effects,but also sonodynamic effects.Therefore,the combination of sonodynamic therapy(SDT)and photodynamic therapy(PDT)using sensitizers for sono-photodynamic therapy(SPDT)provides alternative opportunities for
Mitochondrial shape rapidly changes by dynamic balance of fusion and fission to adjust to constantly changing energy demands of cancer cells.Mitochondrial dynamics balance is exactly regu-lated by molecular motor consisted of myosin and actin cytoskeleton
Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases.A natural fragment of serum albumin,named EPI-X4,has previously been identified as endogenous peptide antagonist and inverse agonist
Ginsenosides are a series of glycosylated triterpenoids which belong to protopanaxadiol(PPD)-,protopanaxatriol(PPT)-,ocotillol(OCT)-and oleanane(OA)-type saponins known as active compounds of Panax genus.They are accumulated in plant roots,stems,leaves,an
Immunotherapy is a rapidly developing area of cancer treatment due to its higher specificity and potential for greater efficacy than traditional therapies.Immune cell modulation through the admin-istration of drugs,proteins,and cells can enhance antitumor
Blood-brain barrier(BBB)damage after ischemia significantly influences stroke outcome.Com-pound LFHP-1c was previously discovered with neuroprotective role in stroke model,but its mechanism of action on protection of BBB disruption after stroke remains un
Protein arginine methyltransferases(PRMTs)have been implicated in the progression of many diseases.Understanding substrate recognition and specificity of individual PRMT would facilitate the discovery of selective inhibitors towards future drug discovery.
Despite considerable progresses in cancer treatment,tumor metastasis is still a thorny issue,which leads to majority of cancer-related deaths.In hematogenous metastasis,the concept of“seed and soil”suggests that the crosstalk between cancer cells(seeds)an
Insulin derivatives such as insulin detemir and insulin degludec are U.S.Food and Drug Administration(FDA)-approved long-acting insulin currently used by millions of people with diabetes.These derivatives are modified in C-terminal B29 lysine to retain in
Multidrug resistance(MDR)mediated by ATP binding cassette subfamily B member 1(ABCB1)is significantly hindering effective cancer chemotherapy.However,currently,no ABCB1-inhibitory drugs have been approved to treat MDR cancer clinically,mainly due to the i